Pooled 24-week TI rates in patients with LR-MDS treated with luspatercept, stratified by ESA exposure and RS status. This forest plot summarizes subgroup-specific 24-week TI rates in patients with TD LR-MDS treated with Lusp. Subgroups were defined based on ESA exposure and RS status: ESA naïve, RS⁺; refractory ESA, RS⁺; refractory ESA/RS^–; and refractory ESA, RS⁺/RS^–, and HTB/LTB mixed populations. Each study is presented with its point estimate and 95% CI, and pooled estimates are shown in a diamond at the bottom using both fixed-effect and random-effects models. Group 2 is the variable that is used to subgroup the studies that built over the included population of patients in the study, as shown in the figure. HTB, high transfusion burden; Lusp, luspatercept.